ArticleArchives of medical science : AMS2017
Leptin receptor expression during the progression of endometrial carcinoma is correlated with estrogen and progesterone receptors.
Article in Archives of medical science : AMS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Single-cell transcriptomics reveals notch regulation in quiescent LEPR⁺ endometrial mesenchymal stem cells.Stem cell research & therapy · 2025Article
- The Relationship Between Leptin Receptor Expression and Endometrial Carcinoma; A Case-Control Study.Iranian journal of pathology · 2023Article
- Revisiting Epithelial Carcinogenesis.International journal of molecular sciences · 2022Article
- Targeting Adipokines in Obesity-Related Tumors.Frontiers in oncology · 2021Review
- Gene expression changes and promoter methylation with the combined effects of estradiol and leptin in uterine tissue of the ovariectomized mice model of menopause.Molecular biology reports · 2020Article
- Estrogen-independent role of ERα in ovarian cancer progression induced by leptin/Ob-Rb axis.Molecular and cellular biochemistry · 2019Article
- Leptin-induced Notch and IL-1 signaling crosstalk in endometrial adenocarcinoma is associated with invasiveness and chemoresistance.World journal of clinical oncology · 2019Article
- Oestrogen receptor alpha PvuII polymorphism and uterine fibroid incidence in Caucasian women.Przeglad menopauzalny = Menopause review · 2018Article
- Gynaecological cancers and leptin: A focus on the endometrium and ovary.Facts, views & vision in ObGyn · 2018Review
- Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation.Disease markers · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe hormone leptin, which is produced in the adipose tissue, may influence tumorigenesis directly via its receptor (Ob-R). Thus, a role for Ob-R in endometrial carcinogenesis has been proposed. However, most studies neither included samples of the entire histological progression of endometrial carcinoma nor examined Ob-R jointly with the estrogen and progesterone receptors (ER and PR, respectively). MATERIAL AND
methodsTo determine the fluctuations of Ob-R, ER, and PR during the histological progression of endometrial carcinoma, we assessed their expression via immunohistochemistry (IHC) in six histological types of endometrium (proliferative, secretory, nonatypical and atypical hyperplasia, and endometrioid and nonendometrioid endometrial carcinoma), in which we performed histopathological and digital scoring for the quantification of receptors.
resultsWe found that Ob-R expression was positively correlated with that of ER and PR (
conclusionsThese results indicate that Ob-R expression fluctuates during endometrial carcinogenesis in correlation with ER and PR, suggesting that Ob-R expression
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.